You are here

  • Home
  • Archive
  • Volume 80, Issue 6
  • Response to: ‘Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak’ by So et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak’ by So et al
  1. Hendrik Schulze-Koops1,
  2. Christof Specker2,
  3. Klaus Krueger3
  1. 1 Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilians-Universitat Munchen, Munich, Germany
  2. 2 Klinik für Rheumatologie und Klinische Immunologie, KEM Kliniken Essen-Mitte, Essen, Germany
  3. 3 Praxiszentrum St Bonifatius, Munchen, Germany
  1. Correspondence to Professor Hendrik Schulze-Koops, Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilians-Universitat Munchen, 80336 Munich, Germany; hendrik.schulze-koops{at}med.uni-muenchen.de

https://doi.org/10.1136/annrheumdis-2020-218235

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank our colleagues So and Tam from Hong Kong for their comments1 on our recommendations for the management of patients with inflammatory rheumatic diseases (IRD) during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 pandemic published in this journal.2 In our manuscript, we have recommended to ensure necessary controls for therapy and disease monitoring; however, we have suggested to always weigh the individual risk of an infection associated with a visit to the doctor’s office (eg, while travelling to and from as well as being present at the medical facility) against the risk of missing controls. In many IRD, temporary prolonged intervals of monitoring patients with stable disease and stable efficacious therapy may well be justified. Thus, in these patients, this measure may help to decrease the risk of getting infected with SARS-CoV-2. However, prolongation of monitoring intervals should be limited in time and as the pandemic continues, patients will have to be monitored again in order to receive appropriate …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors All authors wrote and revised the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles